[gpt3]Summarize this content to 100 words:
April 11, 2025
2 min read
Key takeaways:
- Patients with both psoriasis and hidradenitis suppurativa had the highest overall psoriasis genetic risk score.
- The also had the highest overall non-human leukocyte antigen genetic risk score.
Researchers reported a shared genetic susceptibility of psoriasis and hidradenitis suppurativa, highlighting a need for patients with both conditions to receive unique disease management.
Patients with psoriasis (PSO) or hidradenitis suppurativa (HS) are often at an increased risk of experiencing similar comorbidities, such as cardiovascular disease, obesity and atherosclerosis. Although previous studies have suggested a genetic association between these conditions, the evidence so far has not substantiated this theory.
Data derived from Wiala A, et al. J Am Acad Dermatol. 2025;doi:10.1016/j.jaad.2025.02.015.
“To date, it remains unclear if a dual diagnosis of them is a statistical co-occurrence, or if these patients share genetic vulnerabilities, predisposing them to an increased risk of developing systemic inflammation,” Antonia Wiala, MD, head of the HS specialty at the Clinic Landstrasse in Austria, and colleagues wrote. “This study investigates whether patients who suffer from both, PSO and HS (PSO-SH), show evidence for an increased inflammatory burden by assessing clinical and genetic variables compared to patients with either PSO or HS alone.”
The study found that of 87 patients with PSO-SH, 89% experienced comorbidities. Patients with PSO-SH were 3.09 times (95% CI, 1.56-6.12) more likely than patients with PSO alone and 2.5 times (95% CI, 1.23-5) more likely than patients with HS alone to have worse general physical health.
Patients with PSO-SH were also significantly more likely to have Crohn’s disease (17.1%) compared with patients with PSO alone (3.5%) and patients with HS alone (2%; P = .02 for both). These patients also faced a 2.69 greater risk (95% CI, 1.3-5.81) of having obesity compared with the PSO-only cohort.
Patients with PSO-SH had the highest overall PSO genetic risk score (108.22), followed by patients with PSO (101.18), HS (99.84) and healthy controls (98.58). The researchers also found that patients with PSO-SH had the highest overall non-human leukocyte antigen (non-HLA) genetic risk score (92.87) compared with patients with PSO (91.58) or HS (89.32) alone.
While the HLA region typically confers the strongest association with inflammatory diseases, other genes located both inside and outside of the region are known risk factors for inflammation, the authors explained. This means that high non-HLA scores are associated with an increased risk of developing PSO-SH, making the condition a distinct biological profile compared with HS- and PSO-only disease.
“Genotyping analyses highlight shared genetic susceptibility of HS and psoriasis at non-HLA loci,” the authors concluded. “Patients with both HS and PSO carry the largest genetic burden of investigated non-HLA genes. The shared genetic characteristics help to provide additional evidence that targeted therapies developed for psoriasis patients may also be effective in HS patients.”
The authors concluded that patients with PSO-SH would benefit from being recognized as having a disease separate from PSO and HS with a higher risk for comorbidities, especially Crohn’s disease.
Perspective
This study revealed that patients with HS are more likely than patients without HS to have non-HLA-related genetic risk factors linked to PSO. People with both HS and PSO have even higher genetic risk scores than those with HS or PSO alone, showing that there are likely common genetic influences on the development of HS and PSO, and as genetic risk increases, there is a higher likelihood of multiple inflammatory diseases manifesting together.
Strikingly, 17% of these patients also had Crohn’s disease, which is much higher than the risk associated with either HS or PSO alone and suggests physicians should watch carefully for signs of Crohn’s disease in this population.
Overall, this study reinforces the idea that there are likely genetic factors that lead to a tendency for chronic inflammatory diseases across body systems to present together, which makes the importance of screening for concomitant inflammatory diseases critical in the clinical setting.
Disclosures: Professor of Dermatology at the University of North Carolina at Chapel Hill School of Medicine, Department of Dermatology.
Sources/Disclosures
Collapse
Disclosures:
Wiala reports receiving honoraria and travel support from AbbVie, Biogen, Janssen, Novartis and Sanofi unrelated to this project. Please see the study for all other authors’ relevant financial disclosures.
[/gpt
Source link